Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALPG | P10696 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18982796 | 0.83 | HSD11B1 (0.38) | CNR1CNR2SLC22A12ALDH1A1 | |
| SCHEMBL16797513 | 0.82 | SMN1; SMN2 (0.36) | SLC22A12SMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL18730405 | 0.81 | NPC1 (0.39) | SLC22A12LMNASMN1; SMN2ALDH1A1LGMN | |
| SCHEMBL17765162 | 0.79 | DGAT1 (0.34) | KCNJ11LGMN | |
| SCHEMBL18730380 | 0.79 | KDM4E (0.39) | EGLN1EGLN3SMN1; SMN2HTTTDP1 | |
| SCHEMBL17765339 | 0.77 | CTSL (0.40) | CTSSCTSKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12066413 | 0.77 | KDM4E (0.37) | SLC22A12LMNASMN1; SMN2CTSL | |
| SCHEMBL1759981 | 0.75 | DGAT1 (0.41) | CNR1CNR2EGLN1EGLN3SLC22A12 | |
| SCHEMBL17765237 | 0.73 | SLC22A12 (0.35) | CNR1CNR2EGLN1EGLN3SLC22A12 | |
| SCHEMBL30628308 | 0.70 | TRPV4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10245264-B2 | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180193343-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2018-07-12 | — | — | US | disclosed |
| US-9822130-B2 | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9796733-B2 | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170107236-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107236-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, PDE3A, PDE5A | KCNJ11 379/4885CNR1 1371/4885CNR2 825/4885 |
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | KCNJ11 617/4885CNR1 1627/4885CNR2 1731/4885 |
| US-10245264-B2 | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators | GUCY1A1, GUCY1A2, PDE2A | KCNJ11 443/4885CNR1 744/4885CNR2 931/4885 |
| US-20180193343-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PRKG1, PDE2A | KCNJ11 687/4885CNR1 1122/4885CNR2 1314/4885 |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | KCNJ11 617/4885CNR1 1627/4885CNR2 1731/4885 |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | GUCY1B1, GUCY1A1, GUCY1A2 | KCNJ11 705/4885CNR1 2220/4885CNR2 2278/4885 |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | GUCY1B1, GUCY1A1, GUCY1A2 | KCNJ11 705/4885CNR1 2220/4885CNR2 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.